Test Code GDCRU Gadolinium/Creatinine Ratio, Random, Urine
Reporting Name
Gadolinium/Creat Ratio, Random, UUseful For
Assessing chronic exposure and monitoring effectiveness of dialysis in a random urine collection
Profile Information
Test ID | Reporting Name | Available Separately | Always Performed |
---|---|---|---|
GDCR | Gadolinium/Creat Ratio, U | No | Yes |
CDCR | Creatinine Conc | No | Yes |
Performing Laboratory

Specimen Type
UrineSpecimen Required
Patient Preparation: High concentrations of gadolinium and iodine are known to interfere with most metals tests. If either gadolinium- or iodine-containing contrast media has been administered, a specimen should not be collected for 96 hours.
Supplies: Urine Tubes, 10 mL (T068)
Collection Container/Tube: Clean, plastic urine collection container
Submission Container/Tube: Plastic, 10-mL urine tube or clean, plastic aliquot container with no metal cap or glued insert
Specimen Volume: 3 mL
Collection Instructions:
1. Collect a random urine specimen.
2. See Trace Metals Analysis Specimen Collection and Transport in Special Instructions for complete instructions.
Specimen Minimum Volume
1.5 mL
Specimen Stability Information
Specimen Type | Temperature | Time | Special Container |
---|---|---|---|
Urine | Refrigerated (preferred) | 28 days | |
Ambient | 28 days | ||
Frozen | 28 days |
Special Instructions
Reference Values
0-17 years: not established
≥18 years: <0.8 mcg/g creatinine
Day(s) and Time(s) Performed
Thursday; 8 a.m.
Test Classification
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.CPT Code Information
83018-Gadolinium Concentration
82570-Creatinine Concentration
LOINC Code Information
Test ID | Test Order Name | Order LOINC Value |
---|---|---|
GDCRU | Gadolinium/Creat Ratio, Random, U | 93854-8 |
Result ID | Test Result Name | Result LOINC Value |
---|---|---|
CDCR | Creatinine Conc | 2161-8 |
32873 | Gadolinium/Creat Ratio, U | 93854-8 |
Clinical Information
Gadolinium is a member of the lanthanide series of the periodic table of elements and is considered a nonessential element. Due to its paramagnetic properties, chelated gadolinium is commonly employed as contrast media (gadolinium-based contrast agents: GBCA) for magnetic resonance imaging and computer tomography scanning.
Gadolinium is primarily eliminated via the kidneys, so exposure can be prolonged in patients with renal insufficiency. Patients with reduced renal function and some patients with normal renal function may exhibit a prolonged gadolinium elimination half-life.
To date the only known adverse health effect related to gadolinium retention is a rare condition called nephrogenic systemic fibrosis (NSF). NSF is a relatively uncommon condition in which fibrous plaques develop in the dermis and often in deeper connective tissues. Reported cases have occurred almost exclusively in patients with severe renal disease, and almost all have been associated with prior use of GBCA. NSF is a painful skin disease characterized by thickening of the skin, which can involve the joints and cause significant limitation of motion within weeks to months. Over the past decade, changes in clinical practice guidelines have almost completely eliminated the incidence of NSF. However, the association of NSF and observed elevated gadolinium concentrations is still not fully understood.
Analytic Time
1 dayReject Due To
All specimens will be evaluated at Mayo Clinic Laboratories for test suitability. |
NY State Approved
YesMethod Name
GDCR: Inductively Coupled Plasma-Mass Spectrometry (ICP-MS)
CDCR: Enzymatic Colorimetric Assay
Forms
If not ordering electronically, complete, print, and send a Renal Diagnostics Test Request (T830) with the specimen.